Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study

Takao Takeshima; Kaname Ueda; Mika Komori; Anthony J Zagar; Yongin Kim; Dena H Jaffe; Yasuhiko Matsumori; Koichi Hirata

doi:10.1007/s12325-022-02289-w

Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study

Adv Ther. 2022 Nov;39(11):5176-5190. doi: 10.1007/s12325-022-02289-w. Epub 2022 Sep 12.

Authors

Takao Takeshima¹, Kaname Ueda², Mika Komori³, Anthony J Zagar⁴, Yongin Kim⁴, Dena H Jaffe⁵, Yasuhiko Matsumori⁶, Koichi Hirata⁷

Affiliations

¹ Tominaga Hospital, Osaka, Japan.
² Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan.
³ Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan. komori_mika@lilly.com.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Cerner Enviza, Jerusalem, Israel.
⁶ Sendai Headache and Neurology Clinic, Sendai, Japan.
⁷ Dokkyo Medical University, Mibu, Japan.

Abstract

Introduction: Using data from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVERCOME [Japan]), we describe the current status of the acute treatment of migraine in Japan.

Methods: OVERCOME (Japan) was a cross-sectional, observational, population-based web survey of people with migraine in Japan (met modified International Classification of Headache Disorders criteria or had a physician diagnosis of migraine) conducted between July and September 2020. Respondents reported current acute medication use and effectiveness (assessed using the Migraine Treatment Optimization Questionnaire [mTOQ-4]). Cardiovascular history and risk factors of the respondents were also recorded. Potential unmet acute treatment needs were defined as insufficient effect of current acute treatments (mTOQ-4 score ≤ 5), a history of oral triptan use (and not currently taking any triptan), potential contraindications to triptans due to cardiovascular comorbidities, and/or cardiovascular risk factors.

Results: In total, 17,071 people with migraine in Japan completed the survey; 14,869 (87.1%) of these were currently using acute treatments. Poor effectiveness of current acute treatment was reported by 7170 respondents (42.0%), 900 respondents (5.3%) were former triptan users, 1759 (10.3%) had contraindications to triptans, and 9026 (52.9%) reported at least one cardiovascular risk factor. Overall, 12,649 (74.1%) of OVERCOME (Japan) respondents were categorized into one or more of these groups and were considered to have potential unmet acute treatment needs.

Conclusion: Almost three-quarters of people with migraine in Japan may have potential unmet needs for acute treatment of migraine. There are substantial opportunities for improving care for people with migraine in Japan, including prescription of novel acute medications.

Keywords: Acute treatment; Cardiovascular risk factors; Contraindications; Drug therapy; Headache; Japan; Migraine with aura; Migraine without aura; Triptans.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Cross-Sectional Studies
Humans
Japan / epidemiology
Longitudinal Studies
Migraine Disorders* / drug therapy
Migraine Disorders* / epidemiology
Tryptamines* / therapeutic use

Substances

Tryptamines

Associated data

figshare/10.6084/m9.figshare.20403363